ClinicalTrials.gg
CompletedNCT06086912Updated Feb 1, 2024

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

A Phase 1 interventional study of HR17031 and HR17031 in Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
58th of 81
24 · median 80
Started
2023
with 9 others
Phase 1
48 of 81
4 open now
Registered
51st of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 58th largest by enrollment, is one of 10 that started in 2023, is one of 48 in phase 1, and was the 51st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signing of form before related activities of the experiment and understanding of the procedures and methods of the experiment, willing to strictly follow the clinical trial protocol to complete the experiment.
  2. Both men and women are eligible, aged 18 to 55 years old (inclusive, as determined at the time of signing informed consent form).
  3. (BMI) is between 18 and 27 kg/m2 (inclusive), with male weight ≥ 50 kg and female weight ≥ 45 kg.
  4. Fasting blood glucose level \< 6.1 mmol/L during screening period.

Exclusion criteria

Exclusion Criteria:

-

  1. The following laboratory or auxiliary examination abnormalities are present during the screening period:
  1. Any abnormal laboratory examination with clinical significance. For laboratory examinations with clinical significance, if there is a clear and reasonable reason, retesting can be performed within one week and the retest results used to determine whether the subject meets the criteria;
  2. Abnormalities on 12-lead (ECG) with clinical significance;
  3. Positive for surface antigen (HBsAg), positive for antibody (anti-HCV) (or diagnosed as active hepatitis), or positive for syphilis antibody;
  4. Positive for (HIV) serological test.
  1. The following diseases or medical history are present:
  1. History of hypertension, or systolic blood pressure outside the range of 90-140 mmHg or diastolic blood pressure outside the range of 60-90 mmHg during screening, and judged to have clinical significance by the investigator;
  2. Having a life-threatening disease within the past 5 years (except for basal cell carcinoma or squamous cell carcinoma of the skin);
  3. Having a severe systemic infection within the past 1 month;
  4. Having a history of acute or chronic pancreatitis, symptomatic gallbladder disease, or other risk factors for pancreatitis that may be present;
  5. Having a relevant history of gastrointestinal disease with persistent nausea and vomiting, including but not limited to: having had gastroparesis within the past 6 months that required treatment, unstable (worsening) or poorly controlled (persistent nausea and vomiting) gastroesophageal reflux disease (GERD), or surgery that affects gastric emptying;
  6. Having a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) with a genetic predisposition;
  7. Having a history of any disease or condition that the investigator believes may affect the trial results, including but not limited to a history of cardiovascular, endocrine, neurological, digestive, urinary, hematological, immunological, metabolic diseases, or existing diseases in these systems.
  1. Medications (prescription or over-the-counter), food supplements, vitamins, and Chinese herbal medicines used within 2 weeks before the start of treatment are prohibited. Local application of eye/nose drops and ointments are allowed.
  1. The following conditions are prohibited:
  1. Known or suspected allergy to any component of the study drug;
  2. Participated in any clinical trial of drugs or medical devices within the past 3 months (determined by the signing of form);
  3. Average daily alcohol intake of more than 15 g within the past week (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol white wine); alcohol consumption or positive results on alcohol breath test within 48 hours before treatment;
  4. Smokers (at least 5 cigarettes per day) or non-smokers who smoked within 48 hours before treatment (including the use of nicotine replacement products);
  5. Long-term or within 48 hours before treatment consumption of coffee, tea, chocolate, or soft drinks, such as those containing methylxanthines (theophylline, caffeine, or theobromine) such as cola;
  6. Engaging in strenuous exercise, such as weightlifting, sprinting, long-distance running, cycling, swimming, or playing soccer, within 48 hours before treatment;
  7. Known or suspected history of drug abuse or positive urine drug screening test during screening; unable or unwilling to abstain from smoking, nicotine gum, or transdermal nicotine patch during the trial; unwilling to abstain from alcohol during the trial;
  8. Blood donation within the past month; or blood donation of ≥400 mL within the past 3 months or loss of blood of ≥400 mL due to trauma or major surgery within the past 3 months;
  9. Participants with mental or language disabilities who are unable to fully understand or participate in the trial process;
  10. Participants with poor compliance or poor venous access, or those with a history of fainting;
  11. Pregnant or breastfeeding women;
  12. Participants with the ability to reproduce who have plans to conceive within 10 weeks after the last dose of the study drug or refuse to use medically approved (contraception methods are listed in Appendix 1).
  1. Any other condition judged by the investigator to interfere with the evaluation of the trial results or to be inappropriate for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    sequence 1

    Drug: HR17031

  • Experimental
    sequence 2

    Drug: HR17031

  • Experimental
    sequence 3

    Drug: HR17031

Interventions

  • Receive a single dose of HR17031 at every period (First period:abdomen. Second period. upper arm. Third period: thigh).

  • Receive a single dose of HR17031 at every period (First period:upper arm. Second period: thigh. Third period: abdomen).

  • Receive a single dose of HR17031 at every period (First period:thigh. Second period: abdomen. Third period: upper arm).

06

What researchers measure

Primary outcomes

  1. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t)

    Time frame: Start of treatment up to Day 26

  2. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞)

    Time frame: Start of treatment up to Day 26

  3. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)

    Time frame: Start of treatment up to Day 26

Secondary outcomes

  1. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Time to maximum concentration (Tmax)

    Time frame: Start of treatment up to Day 26

  2. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Apparent terminal half-life (t1/2)

    Time frame: Start of treatment up to Day 26

  3. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Clearance (CL/F)

    Time frame: Start of treatment up to Day 26

  4. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Apparent volume of distribution (Vz/F)

    Time frame: Start of treatment up to Day 26

  5. Safety indicators: Adverse events (AE, including Injection site reactions, Hypoglycemia events, etc.), serious adverse events (SAE).

    Time frame: Screening period up to Day 26

  6. Immunogenicity indicators: anti-Noiiglutide antibodies

    Time frame: Start of treatment up to Day 26

  7. Immunogenicity indicators: anti-INS068 antibodies

    Time frame: Start of treatment up to Day 26

07

Study locations

1 site
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing 100032, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 17, 2023
StartActual
Nov 7, 2023
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06086912
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Nov 7, 2023
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Last update
Feb 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR17031

Start the discussion